The journey a drug makes from the laboratory to the patient’s bedside is very long. After years of clinical research and development, a lengthy administrative procedure needs to be completed. It starts with the granting of a marketing authorisation by the EMA and is followed in Belgium by a reimbursement decision. In order to get a better view on how a drug gets reimbursed in Belgium, Diane Kleinermans (RIZIV-INAMI, President CRM/CTG, Brussels), Marjan Willaert (Policy Advisor – Market Access,, Brussels), and Hanne Wouters (Market Access Advisor,, Brussels) gave an overview on the evaluation and review by the commission for reimbursement of medicines (CRM).